Glenmark Launches Derma Product Winlevi in Key European Markets

Why It Matters

Winlevi introduces a novel, locally acting acne treatment to European patients, creating a high‑growth revenue opportunity and solidifying Glenmark’s position in a competitive dermatology market.

Key Takeaways

• Glenmark launches Winlevi acne cream across Nordics, CEE, Spain
• Winlevi is first topical androgen‑receptor inhibitor in 40 years
• Product targets adolescents 12‑18 and adults with facial acne
• Partnership with Cassiopea enables EU commercialisation
• Launch bolsters Glenmark’s dermatology portfolio and European market share

Pulse Analysis

Acne vulgaris remains one of the most prevalent skin conditions worldwide, affecting up to 95 % of adolescent males and 85 % of females, with half of sufferers continuing into adulthood. Existing topical therapies largely rely on antibiotics or retinoids, which can trigger resistance or irritation. Winlevi’s active ingredient, clascoterone, is a first‑in‑class androgen‑receptor inhibitor that works directly in the sebaceous gland, cutting sebum production without systemic anti‑androgen effects. This novel mechanism addresses a long‑standing therapeutic gap, offering clinicians a safer, more targeted option for both male and female patients.

The European Commission granted marketing authorisation to Cassiopea SpA in October 2025, positioning the Italian biotech as the rights holder across the continent. Glenmark, acting as the commercial partner, is executing a staggered launch strategy that combines direct market entry in the Nordics, Central and Eastern Europe, and Spain with a strategic partnership model in Portugal. By aligning with regional distributors and leveraging its subsidiary Glenmark Specialty SA, the company accelerates market penetration while mitigating regulatory and reimbursement hurdles typical of new dermatology launches.

From a business perspective, Winlevi opens a sizable revenue stream in a market projected to exceed €2 billion annually. As the first new topical acne therapy in four decades, it gives Glenmark a competitive edge against legacy products and emerging biologics. The launch also reinforces the firm’s broader dermatology ambitions, signaling to investors and partners that Glenmark can translate innovative science into commercial success. Continued expansion through additional European partnerships could further boost market share and set the stage for future pipeline candidates in the skin‑health space.